Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2435-2444

  Silber, Jeffrey H ^a   Fridman, Moshe ^b   Shpilsky, Arkady ^b   Even Shoshan, Orit ^b   Smink, Douglas S ^b   Jayaraman, Jai ^b   Fox, Kevin R ^b   Pauly, Mark V ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BLOOD CELL COUNT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; MODEL; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0031859488     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2435     Document Type: Article

References (25)

1. American Society of Clinical Oncology: American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors: Evidence based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
2. Lyman GH, Lyman CG, Sanderson RA, et al: Decision analysis of hematopoietic growth-factor use in patients receiving cancer-chemotherapy. J Natl Cancer Inst 85:488-493, 1993
3. Silber JH, Fridman M, DiPaola RS, et al: First cycle blood counts and subsequent neutropenia, dose reduction, or delay in early stage breast cancer. J Clin Oncol 16:2392-2400, 1998
4. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II. node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
5. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 332:901-906, 1995
6. Bonadonna G, Valagussa P: Dose response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
7. Geller NL, Hakes TB, Petroni GR, et al: Association of disease-free survival and percent of ideal dose in adjuvant breast chemotherapy. Cancer 66:1678-1684, 1990
8. Ludwig Breast Cancer Study Group: Randomized trial of chemoendocrine therapy, endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1:1256-1260, 1984
9. Henderson IC, Hayes DF, Gelman R: Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 6:1501-1515, 1988
10. Redmond C, Fisher B, Wieand HS: The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 67:519-529, 1983
11. Tomin R, Donegan WL: Screening for recurrent breast cancer - Its effectiveness and prognostic value. J Clin Oncol 5:62-67, 1987
12. Chen KK, Montague ED, Oswald ED: Results of irradiation in the treatment of locoregional breast cancer recurrence. Cancer 56:1269, 1985
13. United States Department of Health and Human Services: Vital Statistics of the United States 1990. Vol II. Mortality Part A. Hyattsville, MD, Public Health Service Centers for Disease Control and Prevention, National Center for Health Statistics, Section 6, 1994
14. Beck JR, Kassirer JP, Pauker SG: A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 73:883-888, 1982
15. Beck JR, Pauker SG, Gottlieb JE, et al: A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decisionmaking. Am J Med 73:889-897, 1982
16. Mandelblatt JS, Wheat ME, Monane M, et al: Breast cancer screening for elderly women with and without comorbid conditions: A decision analysis model. Ann Intern Med 116:722-730, 1992
17. Glaspy JA, Bleecker G, Crawford J, et al: The impact of therapy with Filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 29A:S23-S30, 1993 (suppl 7)
18. Sifton DW: 1995 Red Book: Pharmacy's Fundamental Reference. Montvale, NJ, Medical Economics Data, 1995
19. Health Care Financing Administration: Medicare Program: Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 1996 Rates. Washington, DC, United States Department of Health and Human Services, 1996
20. Schulman KA, Glick HA, Rubin H, et al: Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. JAMA 266:3466-3471, 1991
21. Lyman GH, Balducci L: A cost analysis of hematopoietic colony-stimulating factors. Oncology 9:S85-S91, 1995 (suppl)
22. Glaspy JA: Economic outcomes associated with the use of hematopoietic growth factors. Oncology 9:S93-S105, 1995 (suppl)
23. Silber JH, Kaizer H: Marginal analysis and the dose-response curve. Med Pediatr Oncol 16:344-348, 1988
24. United States Renal Data System: 1995 Annual Data Report. Washington, DC, United States Department of Health, The Health Care Funding Administration, April 14, 1995
25. Mark D, Hlatky M, Calidd RM, et al: Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase in acute myocardial infarction. N Engl J Med 332:1418-1424, 1995